PTGS2 (Cyclooxygenase-2) expression and survival among colorectal cancer patients: A systematic review

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 9, 2013, Pages 1490-1497

  Kunzmann, Andrew T ^a,b   Murray, Liam J ^a,b   Cardwell, Chris R ^b   McShane, Charlene M ^b   McMenamin, Úna C ^b   Cantwell, Marie M ^a,b  

^a Centre of Excellence for Public Health   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2;

CANCER PATIENT; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; COLORECTAL CANCER; DISEASE FREE SURVIVAL; HUMAN; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; REVIEW; SYSTEMATIC REVIEW;

COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; DISEASE-FREE SURVIVAL; HUMANS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84884165817     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0263     Document Type: Review

References (60)

1. Wang D, DuBois RN. Prostaglandins and cancer. Gut 2006;55: 115-22.
2. Ristimäki A, Honkanen N, Jänkälä H, Sipponen P, Härkönen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997;57: 1276-80.
3. SoslowRA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000;89: 2637-45.
4. Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin A, et al. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000;21: 139-46.
5. Lee LM, Pan CC, Cheng CJ, Chi CW, Liu TY. Expression of cyclooxygenase- 2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Res 2001;21: 1291-4.
6. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomasand adenocarcinomas. Gastroenterology 1994;107: 1183-8.
7. Ogino S, Kirkner GJ, Nosho K, Irahara N, Kure S, Shima K, et al. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res 2008;14: 8221-7.
8. Zhang H, Sun X. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol 2002;97: 1037-41.
9. Rothwell PM, Price JF, Fowkes FGR, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012;379: 1602-12.
10. RothwellPM, Wilson M, Elwin CE, Norrving B, Algra A,Warlow CP, et al. Long-termeffect of aspirin on colorectal cancer incidence andmortality: 20-year follow-up of five randomised trials. Lancet 2010;376: 1741-50.
11. Rostom A, Dube C, Lewin G, Tsertsvadze A, Barrowman N, Code C, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. preventive services task force. Ann Intern Med 2007;146: 376-89.
12. Chan AT, Ogino S, FuchsCS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302: 649-58.
13. Chuang H, Kardosh A, Gaffney K, Petasis N, Schönthal A. COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro. Mol Cancer 2008;7: 1-13.
14. Seshasai S, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012;172: 209-16.
15. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17: 2815-34.
16. Hewitt P, Ip S, Kwok S, SomersSS, Li K, Leung KL, et al. Laparoscopicassisted vs. open surgery for colorectal cancer. Dis Colon Rectum 1998;41: 901-9.
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327: 557-60.
18. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50: 1088-101.
19. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997;315: 629-34.
20. Duval S, Tweedie R. Trim and fill: a simple funnel-plot?based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56: 455-63.
21. Buecher B, Heymann MF, Lievre A, Nguyen JM, Wilson K, Bezieau S, et al. Cyclo-oxygenase-2 over-expression in sporadic colorectal carcinoma without lymph node involvement. Aliment Pharmacol Ther 2003;18: 731-40.
22. Chen S, Liu J, Li G, Mo F, Xu X, Zhang T, et al. Altered distribution of beta-catenin and prognostic roles in colorectal carcinogenesis. Scand J Gastroenterol 2008;43: 456-64.
23. de Heer P, Gosens MJ, de Bruin EC, Dekker-Ensink NG, Putter H, Marijnen CA, et al. Cyclooxygenase 2 expression in rectal cancer is of prognostic significance in patients receiving preoperative radiotherapy. Clin Cancer Res 2007;13: 2955-60.
24. Fux R, Schwab M, Thon KP, Gleiter CH, Fritz P. Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival. Clin Cancer Res 2005;11: 4754-60.
25. Giralt J, Navalpotro B, Hermosilla E, de Torres I, Espin E, Reyes V, et al. Prognostic significance of vascular endothelial growth factor and cyclooxygenase-2 in patients with rectal cancer treated with preoperative radiotherapy. Oncology 2007;71: 312-9.
26. Huh JW, Kim HR, Lee JH, Kim YJ. Comparison of cyclooxygenase-2 and CD44 mRNA expression in colorectal cancer and its relevance for prognosis. Virchows Archiv 2009;454: 381-7.
27. Inafuku Y, Furuhata T, Tayama M, Okita K, Nishidate T, Mizuguchi T, et al. Matrix metalloproteinase-2 expression in stromal tissues is a consistent prognostic factor in stage II colon cancer. Cancer Sci 2009;100: 852-8.
28. Jimenez-Anula J, Luque RJ, Gaforio JJ, Delgado M. [Cyclooxygenase- 2 expression as a prognostic factor in sporadic colorectal cancer]. Cirugia Espanola 2005;78: 39-44.
29. Joo Y, Kim H, Min S, Lee WS, Park CH, Park CS, et al. Expression of cyclooxygenase-2 protein in colorectal carcinomas. Int J Gastrointest Cancer 2002;31: 147-54.
30. Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000;6: 4064-8.
31. Midgley RS, McConkey CC, Johnstone EC, Dunn JA, Smith JL, Grumett SA, et al. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J Clin Oncol 2010;28: 4575-80.
32. Tomozawa S, Tsuno N, Sunami E, Hatano K, Kitayama J, Osada T, et al. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 2000;83: 324-8.
33. Peng ZH, Wan DS, Li LR, Chen G, Lu ZH, Wu XJ, et al. Expression of COX-2, MMP-2, and VEGF in stage II and III colorectal cancer and the clinical significance. Hepatogastroenterology 2011;58: 369-76.
34. Petersen S, Haroske G, Hellmich G, Ludwig K, Petersen C, Eicheler W. COX-2 epression in rectal carcinoma: immunohistochemical pattern and clinical outcome. Anticancer Res 2002;22: 1225-30.
35. Ong CW, Kim LG, Kong HH, Low LY, Iacopetta B, Soong R, et al. CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol 2010;23: 450-7.
36. Pancione M, Forte N, Sabatino L, Tomaselli E, Parente D, Febbraro A, et al. Reduced beta-catenin and peroxisome proliferator-activated receptor- expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome. Hum Pathol 2009;40: 714-25.
37. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 2004;10: 8465-71.
38. Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999;282: 1254-7.
39. Sundov Z, Kunac N, Capkun V, Kalebic M, Druzijanic N, Puljak L, et al. Cyclooxygenase-2 in dukes B colon cancer. Hepatogastroenterology 2011;58: 763-768.
40. Wan XB, Pan ZZ, Ren YK, Ding PR, Chen G, Wan DS. [Expression and clinical significance of metastasis-related tumor markers in colorectal cancer]. Aizheng 2009;28: 950-4.
41. Yamauchi T, Watanabe M, Kubota T, Hasegawa H, Ishii Y, Endo T, et al. Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer. Dis Colon Rectum 2002;45: 98-103.
42. Yamac D, Celenkoglu G, Coskun U, Akyurek N, Akcali Z, Dursun A, et al. Prognostic importance of COX-2 expression in patients with colorectal cancer. Pathol Res Pract 2005;201: 497-502.
43. Wu A, Gu J, Ji J, Li Z, Xu G. Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients' prognosis. World J Gastroenterol 2003;9: 1990-4.
44. Lim SC, Lee TB, Choi CH, Ryu SY, Min YD, Kim KJ. Prognostic significance of cyclooxygenase-2 expression and nuclear p53 accumulation in patients with colorectal cancer. J Surg Oncol 2008;97: 51-6.
45. Zhou ZG, Wu XJ, Li LR, Peng ZH, Ding PR, Wang RJ, et al. A multivariate analysis of prognostic determinants for stages II and III colorectal cancer in 141 patients. Chin Med J 2011;124: 2132-5.
46. Rosenthal R. The file drawer problem and tolerance for null results. Psychol Bull 1979;86: 638.
47. Jang SM, Jun YJ, Na Woong, Jang SH, Min KW, Song YS, et al. Clinicopathologic significance of cyclooxygenase-2 overexpression in colorectal adenocarcinoma. Basic Appl Pathol 2010;3: 14-20.
48. Cahlin C, Lonnroth C, Arvidsson A, Nordgren S, Lundholm K. Growth associated proteins in tumor cells and stroma related to disease progression of colon cancer accounting for tumor tissue PGE2 content. Int J Oncol 2008;32: 909-18.
49. Denkert C, Koch I, Von Keyserlingk N, Noske A, Niesporek S, Dietel M, et al. Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2. Mod Pathol 2006;19: 1261-9.
50. El-Serafi MM, Bahnassy AA, Ali NM, Eid SM, Kamel MM, Abdel-Hamid NA, et al. The prognostic value of c-kit, K-ras codon 12, and p53 codon 72 mutations in egyptian patients with stage II colorectal cancer. Cancer 2010;116: 4954-64.
51. Debucquoy A, Libbrecht L, Roobrouck V, Goethals L, McBride W, Haustermans K. Morphological features and molecular markers in rectal cancer from 95 patients included in the european organisation for research and treatment of cancer 22921 trial: prognostic value and effects of preoperative radio (chemo) therapy. Eur J Cancer 2008;44: 791-7.
52. Watwe V, Javle M, Lawrence D, Groth J, Iyer R, El-Hajjar D, et al. Cyclooxygenase-2 (COX-2) levels before and after chemotherapy: a study in rectal cancer. Am J Clin Oncol 2005;28: 560-4.
53. Debucquoy A, Roels S, Goethals L, Libbrecht L, Van Cutsem E, Geboes K, et al. Double blind randomized phase II study with radiation + 5-fluorouracil +/- celecoxib for resectable rectal cancer. Radiother Oncol 2009;93: 273-8.
54. Ogino S, Brahmandam M, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Neoplasia 2006;8: 458-64.
55. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012;367: 1596-606.
56. Karnes WE Jr, Shattuck-Brandt R, Burgart LJ, DuBois RN, Tester DJ, Cunningham JM, et al. Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res 1998;58: 5473-7.
57. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23: 609-18.
58. Funkhouser WK Jr, Lubin IM, Monzon FA, Zehnbauer BA, Evans JP, Ogino S, et al. Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology. J Mol Diagn 2012;14: 91-103.
59. McCowan C, Munro AJ, Donnan PT, Steele RJC. Use of aspirin postdiagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. Eur J Cancer 2013;49: 1049-57.
60. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69: 1366-72.